| Project/Area Number |
26670482
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
ITO MASAHIKO 浜松医科大学, 医学部, 助教 (50385423)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | B型肝炎ウイルス / CRISPR/Cas9 / CRISPRi / オカルトHBV / cccDNA / HBV / 潜伏感染 / CRISPR/CAS9 / HBV DNAの切断 / 転写抑制 |
|---|
| Outline of Final Research Achievements |
Hepatitis B virus (HBV) infection is a major cause of acute and chronic hepatitis and is closely associated with development of cirrhosis and hepatocellular carcinoma (HCC) worldwide. Treatments or drags for the clearance of HBV cccDNA have not been established until now. CRISPR/Cas9 system has possibility to completely eliminate cccDNA in the nuclear of hepatocyte. In this study, we applied CRISPR/Cas9 and CRISPRi system to HBV infected cells, and revealed that these system could repress the transcription of pgRNA and expression of HBs and HBe antigen.
|
